Neutrophil CD64 – A potential biomarker in patients with complicated intra-abdominal infections? – A literature review by Dimitrov, Evgeni et al.
NEUTROPHIL CD64 – A POTENTIAL BIOMARKER
IN PATIENTS WITH COMPLICATED
INTRA-ABDOMINAL INFECTIONS? –
A LITERATURE REVIEW
EVGENI DIMITROV1*, EMIL ENCHEV1, KRASIMIRA HALACHEVA2,
GEORGI MINKOV1 and YOVCHO YOVTCHEV1
1Department of Surgical Diseases, University Hospital “Prof. Dr. Stoyan Kirkovich”,
Stara Zagora, Bulgaria
2Faculty of Medicine, Department of Immunology, Trakia University,
Stara Zagora, Bulgaria
(Received: 9 November 2017; accepted: 12 December 2017)
Complicated intra-abdominal infections (cIaIs) respresent a serious cause of
morbidity and mortality. Early diagnosis and well-timed treatment can improve
patients’ outcome, whereas the delay in management often result in rapid progression
to circulatory collapse, multiple organ failure, and death. Neutrophil CD64 antigen
expression has been studied for several years as infectious and sepsis biomarker and
has several characteristics that make it good for clinical employment. It has been
suggested to be predictive of positive bacterial cultures and a useful test for
management of sepsis and other signiﬁcant bacterial infections. Our review concluded
that the neutrophil CD64 expression could be a promising and meaningful biomarker
in patients with cIaIs. It shows good potential for evaluating the severity of the disease
and could give information about the outcome. However, more large studies should be
performed before using it in clinical practice.
Keywords: biomarkers, CD64, prognosis, complicated intra-abdominal
infections, sepsis
Introduction
Complicated intra-abdominal infections (cIaIs) are associated with mortality
rates of 25% [1]. At the beginning of the 21st century, cIaIs remain responsible for
20% of sepsis in intensive care units (ICUs). Thus, cIaIs represent the second
common cause for infectious morbidity and mortality after pneumonia [2, 3].
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Intra-abdominal infections (IaI) are classiﬁed as uncomplicated or complicated
according to the spread of infection. Uncomplicated infections involve inﬂammation
of the gastrointestinal organs without anatomic disruption. Usually, there are no
difﬁculties with their treatment; but when it is delayed or incorrect, or the infection is
nosocomial, the risk of evolution into a complicated one becomes considerable [4, 5].
cIaIs extend beyond the source organ into the peritoneal cavity and cause localized or
diffuse peritonitis [6]. They are usually accompanied with sepsis that can evolve into
septic shock and eventually to multiple organ dysfunction syndrome and death.
Sepsis is a life-threatening organ dysfunction based on dysregulated host
response to infection – sepsis 3 deﬁnitions [7]. Organ dysfunction is deﬁned as an
increase of two points or more in the sequential organ failure assessment (SOFA)
Score (sepsis clinical criteria). For patients with infections, an increase of two
SOFA points gives an overall mortality rate of 10%. Patients with suspected
infection who are likely to have a prolonged ICU stay or to die in the hospital can
promptly be identiﬁed at the bedside with quick SOFA (qSOFA). qSOFA uses
these 3 criteria (HAT):
Hypotension: systolic blood pressure less than or equal to 100 mmHg,
Altered mental status: (Glasgow Coma Scale less than 15 points),
Tachypnea: respiratory rate greater than or equal to 22 min.
Septic shock is the presence of sepsis with (despite adequate volume
resuscitation) both the persistent hypotension-requiring vasopressors to maintain
mean arterial pressure greater than or equal to 65 mm Hg and lactate greater than or
equal to 2 mmol/L. With these criteria, hospital mortality is in excess of 40% [8].
cIaIs include a wide range of patient populations, which make it difﬁcult to
suggest a general treatment regimen and show the need of an individual approach
to each patient. There are a lot of different factors inﬂuencing the prognosis of
patients with cIaIs, including poor nutrition, preexisting diseases, advanced age,
prolonged hospitalization before therapy, immunosuppression, diffuse peritonitis,
septic shock, poor source control, organ failures, and presence of nosocomial
agents [9]. Sepsis remains important and leading cause of morbidity and mortality
in cIaIs [10]. Early diagnosis and well-timed treatment can improve patients’
outcome [11, 12]; therefore, there is an instant need of exact methods that can
diagnose sepsis in early stages, make early prognostic evaluation, and deﬁne the
aggressiveness of conservative treatment and surgical management. Great hopes
for dealing with these problems are focused on the group of biomarkers.
In 2010, Pierrakos and Vincent [13] established that nearly 180 different
biomarkers for sepsis have been described in the literature to date. Nowadays, this
number is surely larger. Some of them like white blood cell (WBC) count,
erythrocyte sedimentation rate, C-reactive protein (CRP), and procalcitonine
(PCT) are already used in clinical practice, but their efﬁcacy is limited by the
lack of sufﬁcient sensitivity and speciﬁcity. At this moment, one thing is for sure,
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there is no ideal sepsis biomarker and we are still looking for it. In our article, we
reviewed various studies that show the neutrophil CD64 potential for the
diagnosis, prognosis, and disease severity.
Neutrophil CD64
CD64 antigen expression on neutrophils has been under investigation for
several years as a biomarker of infection and sepsis. It has several characteristics
that make this marker well suited for clinical application: CD64 expression on
resting neutrophils is low and after activation, it is signiﬁcantly upregulated within
few hours. Once the activation stimulus disappears, CD64 expression returns to its
basal level in few days. Moreover, CD64 is relatively stable after blood collection
and the assay is straightforward and requires only small sample volume. Last but
not least, CD64 expression represents a physiological process, which plays a key
role in the innate immune response: neutrophils acting as phagocytes [14].
CD64, a leukocyte surface antigen, is a high-afﬁnity Fc receptor, which
binds to monomeric IgG. The Fc receptors are involved with the innate and
adaptive immune response, stimulating either phagocytosis or antibody-mediated
cytotoxicity [15]. Neutrophil CD64 expression rapidly increases in the presence of
microbial wall components, complement split products, and some proinﬂamma-
tory cytokines, such as interferon gamma and granulocyte colony-stimulating
factor [16]. CD64 is constitutively expressed on neutrophils at low levels during
the absence of infection, but when activated by proinﬂammatory cytokines, it is
rapidly upregulated up to tenfold higher levels [14]. The upregulation of CD64 on
the polymorphonuclear (PMN) cell surface is considered to be an early step in the
innate immune response to bacterial infection [17, 18]. CD64 expression increases
hours after activation of innate immunity and therefore it can reﬂect at the very
early stages of infection and can help make early diagnosis and prognosis. The
CD64 index has been suggested to be predictive of positive bacterial cultures and a
useful test for management of sepsis and other signiﬁcant bacterial infections [19].
The most common method for neutrophil CD64 determination is ﬂow
cytometry. Unfortunately, this determination lacks standardization.
Diagnostic Value
First, in 2006, Davis et al. [17] in prospective analysis of 100 blood samples
from the emergency department patients concluded that neutrophil CD64 expres-
sion quantitation provides improved diagnostic detection of infection/sepsis with
sensitivity of 87.9% and speciﬁcity of 71.2% compared with the standard
diagnostic tests used in current medical practice. In 2012, Gros et al. [20] in
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their study including 293 patients with a Simpliﬁed Acute Physiology Score II of
45 (31–59) found bacterial infection in 148 patients and documented systemic
inﬂammatory response syndrome or non-bacterial infection in 145 patients. A
CD64 index >2.2 predicted bacterial infection with a speciﬁcity and sensitivity of
89% and 63%, respectively. The authors showed that because of its weak
sensitivity for bacterial infection, CD64 index should be combined with other
more sensitive biomarkers. Gibot et al. [21] in their study with 300 patients
showed that serum concentrations of PMN CD64 index were higher in patients
with sepsis compared with all others. The cut-off CD64 index was 1.62. A
Brazilian study conducted in 2014 including 93 patients indicates that high
expression of CD64 is an important indicator in the diagnosis of infection and
sepsis [22]. In 2014, Righi et al. [23] evaluated 93 consecutive patients presented
with infection signs on admission. CD64 neutrophil expression, CRP, and WBC
count were investigated. CRP and CD64 showed a signiﬁcant difference between
septic and non-septic patients, respectively. Receiver operating characteristic
(ROC) curves of CD64, CRP, and WBC count showed the superiority of CD64:
considering a cut-off of 2000 antibody-binding capacity for infection, sensitivity
was 90.2%, and speciﬁcity was 96.9% in comparison with CRP (85.2% sensitivity
and 46.9% speciﬁcity for cut-off of 10 mg/L). CD64 neutrophil expression, but not
CRP, was able to differentiate the septic stages (p< 0.001). Their conclusion is that
neutrophil CD64 represents a sensitive and speciﬁc marker for the early diagnosis of
systemic infections in adult patients admitted to ICU, superior to traditional hemato-
logical parameters and CRP. In 2014, prospective observational study with
468 patients, Dimoula et al. [24] showed that septic patients had higher nCD64
expression at admission than did non-septic patients. A cut-off nCD64 expression at
admission of 230 median ﬂuorescence intensity (MFI) identiﬁed sepsis with a
sensitivity of 89% (81%–94%) and speciﬁcity of 87% (83%–90%). Septic patients
receiving inappropriate empirical antibiotics had persistently elevated nCD64 expres-
sion, whereas expression decreased over time in patients receiving appropriate
antibiotics. In non-septic patients, an increase in nCD64 expression ≥40 MFI
predicted ICU-acquired infection (n= 29) with a sensitivity of 88% and speciﬁcity
of 65%. Neutrophil CD64 expression was associated with the severity of sepsis.
Patients with septic shock had signiﬁcantly higher nCD64 expression than did other
septic patients [median (lower–upper quartile) 413 (324–493) vs. 331 (268–395)MFI;
p< 0.001]. Dimoula et al. concluded that measurement of nCD64 expression at ICU
admission, especially when combined with CRP concentrations, is useful in diagnos-
ing sepsis. Serial determinations of nCD64 could be used for monitoring purposes.
On the basis of 2013 meta-analysis with a total of 26 studies including 3,944
patients, neutrophil CD64 expression could be a promising and meaningful
biomarker for diagnosing bacterial infection with sensitivity of 76% and
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speciﬁcity of 85% [16]. Nevertheless, more large prospective studies should be
carried out before the neutrophil CD64 test is used widely in the clinical setting
because of the various cut-off values.
Meta-analysis from 2015 including a total of eight studies with 1,986 patients
showed that nCD64 expression is a helpful marker for an early diagnosis of sepsis in
critically ill patients with sensitivity and speciﬁcity 76% [95% conﬁdence interval
(CI): 73%–78%] and 85% (95%CI: 82%–87%), respectively [25]. The results of the
test should not be used alone to diagnose sepsis, but instead should be interpreted in
combination with medical history, physical examination, and other test results. The
authors could not determine the ideal cut-off point for the nCD64 test, because there
were several assay methods for nCD64 test and they did not have enough data.
However, all of these studies did not show which patients are from surgical
department or have abdominal sepsis (except Dimoula et al.). Maybe, there will be
a beneﬁt for future meta-analysis including only surgical patients that could
determine the diagnostic potential of nCD64 for cIaIs (Table I).
Disease Severity Value
Neutrophil CD64 expression is useful not only for the diagnosis of sepsis,
but several authors have also reported its value as severity marker: patients with
septic shock generally show higher CD64 values than patients with sepsis [14].
Livaditi et al. [26] studied several biomarkers that best evaluate the severity of
sepsis [via Acute Physiology And Chronic Health Evaluation II Score (APACHE
II)] – CD64, IL-8, and IL-6 (p< 0.01), and the severity of organ failure (via
SOFA) – CD64 and IL-8. CD64 expression was associated with mortality within
28 days (OR= 1.3, p= 0.01) and ROC curve analysis showed high sensitivity and
speciﬁcity for predicting sepsis stages and the 28-day mortality. The authors
Table I. Characteristics of the studies
Authors Year
Type of
study
Medical
department
Number of
patients
Cut-off
value
Sensitivity
(%)
Speciﬁcity
(%)
Davis et al. 2006 Prospective Emergency
department
100 2000
MESF
87.9 71.2
Gros et al. 2012 Prospective ICU 293 2.2 index 63 89
Gibot et al. 2012 Prospective ICU 300 1.62 index 84.4 95.2
Farias et al. 2014 Prospective ICU 93 1.51% No data No data
Righi et al. 2014 Prospective ICU 93 2000 ABC 90.2 96.9
Dimoula et al. 2014 Prospective ICU 468 230 MFI 89 87
Li et al. 2013 Meta-analysis – 3,944 No cut-off 76 85
Wang et al. 2015 Meta-analysis – 1,986 No cut-off 76 85
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conclude that there is an early increase of neutrophil CD64 expression during
sepsis. Based on this single measurement, it is possible to reliably assess the stage,
detect the severity, and predict the 28-day mortality of sepsis. A prospective study
of Hsu et al. [27] with 66 patients showed that CD64 expression and the ratio of
CD64/CD16 signiﬁcantly increased with the severity of sepsis. CD64, CD64/
CD16, and PCT all signiﬁcantly predicted sepsis, septic shock, and bacteremia.
CD64 was associated with mortality and was better than PCT for identifying
patients who required treatment with antibiotics. Icardi et al. [19] found in 109
patients over a 2-month period that a CD64 index of <1.19 was predictive of “no
growth” blood culture results. An index of >1.19 was predictive of an ultimate
clinical and/or culture diagnosis of infection with a sensitivity and speciﬁcity of
94.6% and 88.7%, respectively. Positive and negative predictive values were
89.8% and 94%, respectively. The CD64 index is a useful and inexpensive test for
improving the diagnosis and management of hospital patients with bacterial
infection. It can be readily performed by clinical laboratories and could result
in considerable savings for the institution.
Prognostic Value
According to some authors, nCD64 contains prognostic signiﬁcance as well.
However, the available data are highly contradictory. Some publications demon-
strated that survival could be predicted by a low expression of CD64 [14]. Fischer
et al. [28] showed in their study that CD64 expression was greater in patients with
septic shock than in patients without sepsis. Moreover, CD64 expression was only
initially and transiently elevated in most survivors (9/10) and non-survivors (8/12)
of septic shock. These authors concluded that decreased neutrophil CD64
expression in an acutely ill population with septic shock may reﬂect the develop-
ment of a non-responsive state as well as the early downregulation of neutrophil
activation prior to the resolution of an ongoing infection. Chen et al. [29] in their
cohort consisting of 797 ICU patients found that CD64 had the greatest power for
predicting ICU mortality other than APACHE II scores. They showed that CD64
provides superior capability to predict ICU mortality compared with CRP. In
addition, the combined use of CD64 levels and APACHE II scores signiﬁcantly
improved the accuracy in predicting ICU mortality. CD64 index is higher in non-
survivors (2.94± 1.86) than in survivors (1.62± 1.15). Overall, CD64 is a useful
biomarker for assessing the health status of patients enrolled in the ICU.
Other authors indicated that high nCD64 could be a marker of favorable
prognosis. Probably, the small patient groups and the study designs explain
these conﬂicting ﬁndings. Danikas et al. [30] showed in their publication that
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reduced phagocytic activity of neutrophils during the ﬁrst 24 h after admission
was a negative predictor for survival. Increased expression of CD64 antigen on
PMN cells and monocytes was favorably correlated to the patients’ survival. In
multivariate analysis, the phagocytic activity of PMNs was the only indepen-
dent predictor factor for survival. Patients with PMN phagocytic activity (37%)
had higher expression of CD64 on monocytes and PMNs and better outcome.
Reduced phagocytic activity of neutrophils may represent a state of neutrophil
inactivation. Cid et al. [31] prospectively included 132 patients with fever
≥38 °C (≥100.4 °F) during the last 24 h and measured CD64 expression on
neutrophils the day after the admission at the emergency department. They
followed the patients until full recovery or death. There were 115 (87%)
patients with bacterial infection and 108 (94%) of them survived. There were
17 (13%) patients without bacterial infection and 12 (71%) of them survived.
Patients with bacterial infection and patients who survived showed a CD64
index higher when compared with patients without bacterial infection and
patients who died, respectively (3.7 ± 3.2 vs. 2.5 ± 2.3; p = 0.03 and 3.7 ± 3.1
vs. 1.7 ± 0.6; p = 0.002; Mann–Whitney U test). The ROC curve analysis for
detecting bacterial infection and predicting survival with the CD64 index
showed an area under curve of 0.66 (95% CI: 0.52–0.8; p = 0.03) and 0.71
(95% CI: 0.57–0.85; p = 0.01), respectively. Diagnostic accuracy and prog-
nostic value of CD64 expression was good in adult patients with fever.
Conclusions
Because of the complexity of sepsis and sepsis pathophysiological mechan-
isms, probably in the near future, it will be very hard to ﬁnd the ideal biomarker.
However, we think that neutrophil CD64 deserves attention, because it demon-
strates very good sensitivity and speciﬁcity as diagnostic marker for sepsis. Our
opinion is that nCD64 could be a reliable diagnostic biomarker in patients with
cIaIs. It also shows good potenitial for deﬁning the disease severity, but there is
contradictory data about its prognostic value. Of course, further large multicenter
studies especially with more surgical patients should be performed, before using
this biomarker in clinical practice.
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